Skip to main content

Table 5 Results of cost-effectiveness analysis

From: Cost-effectiveness analysis of gemtuzumab ozogamicin for the treatment of de novo CD33-positive Acute Myeloid Leukaemia (AML) in Italy

Parameter

GO + DA (a)

DA (b)

Difference

(a-b)

ICER,

a vs b (€)

Total costs (€)

162,424

162,708

-285

-

Life Years (LYs)

6.42

5.75

0.67

-425

QALYs

4.69

4.19

0.50

-568

  1. DA = daunorubicin and cytarabine, GO = gemtuzumab ozogamicin, ICER = incremental cost-effectiveness ratio, LY = life year, QALY = quality adjusted life year
Back to article page

BMC Health Services Research

ISSN: 1472-6963

Contact us